Investing.com··Itai SmidtNovo Nordisk Reassesses Growth Outlook Following CagriSema Trial Setback
Novo Nordisk stock drops 15.9% after CagriSema obesity drug fails trial versus competitor tirzepatide, signaling intensifying competition in the GLP-1 market despite Wegovy's strength.
LLYNVOGLP-1 drugsWegovy